Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

HIVR4P 2016: The Long Tail Problem -- Injectable PrEP Trial To Be Extended Due to Drug Persistence

A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of people who were given the experimental injectable drug cabotegravir as HIV pre-exposure prophylaxis (PrEP), the drug was still measurable in their body a full year after their last injection.

alt

Read more:

IDWeek 2016: HIV+ Men and Men on PrEP in Boston See Large Increase in Sexually Transmitted Infections

Rates of gonorrhea, syphilis, and chlamydia have risen steeply at Fenway Health in Boston since 2011, according to presentation last week at IDWeek in New Orleans. Being HIV-positive and using pre-exposure prophylaxis (PrEP) to prevent HIV were associated with higher risk of getting-sexually transmitted infections (STIs), but more frequent STI testing and treatment could potentially help reduce the numbers.

alt

Read more:

IDWeek 2016: Electronic Health Records Can Help Select Candidates for HIV PrEP

A machine learning algorithm used to analyze electronic health records (EHRs) identified high-risk individuals who could potentially benefit from HIV pre-exposure prophylaxis (PrEP), according to a report presented this week at IDWeek 2016 in New Orleans. Out of 800,000 patients in a large EHR database, more that 8000 were found to be potential PrEP candidates.

alt

Read more:

HIV Glasgow: Tests of Online PrEP Purchases Find No Fakes and Adequate Drug Levels

A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate levels of both drugs in their blood, and no sample suggesting counterfeit drugs.

alt

Read more:

HIVR4P 2016: Some Americans Who Need PrEP the Most Face the Greatest Barriers

The personal values and moral judgments of healthcare providers are likely to interfere with the appropriate provision of HIV pre-exposure prophylaxis (PrEP), Sarah Calabrese of Yale University reported at the HIV Research for Prevention conference (HIVR4P 2016) in Chicago last week. This was one of several presentations which highlighted inequalities in access to PrEP in the U.S. In a plenary talk, Noël Gordon of the Human Rights Campaign reminded delegates that white people make up 27% of new HIV diagnoses but 74% of PrEP users. There are also inequalities in terms of age and gender.

alt

Read more: